--- title: "PMGC | 10-Q: FY2026 Q1 Revenue: USD 681.99 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286632005.md" datetime: "2026-05-16T03:54:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286632005.md) - [en](https://longbridge.com/en/news/286632005.md) - [zh-HK](https://longbridge.com/zh-HK/news/286632005.md) --- # PMGC | 10-Q: FY2026 Q1 Revenue: USD 681.99 K Revenue: As of FY2026 Q1, the actual value is USD 681.99 K. EPS: As of FY2026 Q1, the actual value is USD -11.175. EBIT: As of FY2026 Q1, the actual value is USD -2.922 M. #### Segment Revenue - Corporate, Treasury and Biosciences revenue was $0 for the three months ended March 31, 2026. - IT Packaging Solutions revenue was $132,024 for the three months ended March 31, 2026. - Precision Engineering and Machining revenue was $549,970 for the three months ended March 31, 2026. - Total Revenue was $681,994 for the three months ended March 31, 2026, an increase of $681,994 compared to $0 for the same period in 2025. #### Cost of Sales - Corporate, Treasury and Biosciences cost of sales was $0 for the three months ended March 31, 2026. - IT Packaging Solutions cost of sales was $79,135 for the three months ended March 31, 2026. - Precision Engineering and Machining cost of sales was $372,385 for the three months ended March 31, 2026. - Total Cost of Sales was $451,520 for the three months ended March 31, 2026, compared to $0 for the same period in 2025. #### Gross Profit - Corporate, Treasury and Biosciences gross profit was $0 for the three months ended March 31, 2026. - IT Packaging Solutions gross profit was $52,889 for the three months ended March 31, 2026. - Precision Engineering and Machining gross profit was $177,585 for the three months ended March 31, 2026. - Total Gross Profit was $230,474 for the three months ended March 31, 2026, an increase of $230,474 compared to $0 for the same period in 2025. #### Expenses - Corporate, Treasury and Biosciences expenses were $2,628,257 for the three months ended March 31, 2026. - IT Packaging Solutions expenses were $122,192 for the three months ended March 31, 2026. - Precision Engineering and Machining expenses were $813,199 for the three months ended March 31, 2026. - Total Operating Expenses were $3,563,648 for the three months ended March 31, 2026, an increase of $2,361,924 compared to $1,201,724 for the same period in 2025. #### Other Income (Expense) - Corporate, Treasury and Biosciences other income (expense) was - $1,603,506 for the three months ended March 31, 2026. - IT Packaging Solutions other income (expense) was $0 for the three months ended March 31, 2026. - Precision Engineering and Machining other income (expense) was - $50,080 for the three months ended March 31, 2026. - Total Other Income (Expense) was - $1,653,586 for the three months ended March 31, 2026, an unfavorable variance of - $1,274,499 compared to - $379,087 for the same period in 2025. #### Net Loss from Continuing Operations - Corporate, Treasury and Biosciences net loss from continuing operations was - $4,231,763 for the three months ended March 31, 2026. - IT Packaging Solutions net loss from continuing operations was - $69,303 for the three months ended March 31, 2026. - Precision Engineering and Machining net loss from continuing operations was - $685,694 for the three months ended March 31, 2026. - Total Net Loss from Continuing Operations was - $4,986,760 for the three months ended March 31, 2026, an unfavorable variance of - $3,405,949 compared to - $1,580,811 for the same period in 2025. #### Total Assets - Corporate, Treasury and Biosciences total assets were $10,819,442 as of March 31, 2026. - IT Packaging Solutions total assets were $353,851 as of March 31, 2026. - Precision Engineering and Machining total assets were $14,860,025 as of March 31, 2026. - Total Assets (Company-wide) were $26,033,318 as of March 31, 2026, compared to $12,868,473 as of December 31, 2025. - Current Assets were $16,386,587 as of March 31, 2026, an increase of $9,515,332 compared to $6,871,255 as of December 31, 2025. - Non-current assets were $9,646,731 as of March 31, 2026. #### Total Liabilities - Corporate, Treasury and Biosciences total liabilities were $9,596,935 as of March 31, 2026. - IT Packaging Solutions total liabilities were $148,327 as of March 31, 2026. - Precision Engineering and Machining total liabilities were $3,681,603 as of March 31, 2026. - Total Liabilities (Company-wide) were $13,426,865 as of March 31, 2026, compared to $5,031,111 as of December 31, 2025. - Current Liabilities were $11,297,734 as of March 31, 2026, an increase of $7,355,438 compared to $3,942,296 as of December 31, 2025. - Non-current liabilities were $2,129,131 as of March 31, 2026. #### Total Equity - Corporate, Treasury and Biosciences total equity was $1,222,507 as of March 31, 2026. - IT Packaging Solutions total equity was $205,524 as of March 31, 2026. - Precision Engineering and Machining total equity was $11,178,422 as of March 31, 2026. - Total Equity (Company-wide) was $12,606,453 as of March 31, 2026, compared to $7,837,362 as of December 31, 2025. #### Gross Margin Percentage - The Overall Gross Profit Percentage was 33.79% for the three months ended March 31, 2026. - Pacific Sun – Sale of IT packaging gross margin was 40.06% for the three months ended March 31, 2026. - AGA – Machine work gross margin was 34.18% for the three months ended March 31, 2026. - SVM-Machine work gross margin was 30.97% for the three months ended March 31, 2026. #### Research and Development Expenses - Research and development expenses were $47,061 for the three months ended March 31, 2026, an increase of $14,628 compared to $32,433 for the same period in 2025. #### Office and Administrative Expenses - Office and administrative expenses were $1,381,736 for the three months ended March 31, 2026, an increase of $1,172,705 compared to $209,031 for the same period in 2025. #### Consulting Fees - Consulting fees were $1,210,015 for the three months ended March 31, 2026, an increase of $662,458 compared to $547,557 for the same period in 2025. #### Professional Fees - Professional fees were $592,023 for the three months ended March 31, 2026, an increase of $325,555 compared to $266,468 for the same period in 2025. #### Investor Relations Expenses - Investor relations expenses were $16,133 for the three months ended March 31, 2026, a decrease of $53,817 compared to $69,950 for the same period in 2025. #### Net Working Capital - Net working capital was $5,088,853 as of March 31, 2026, an increase of $2,159,894 compared to $2,928,959 as of December 31, 2025. #### Accumulated Deficit - Accumulated deficit was - $25,984,699 as of March 31, 2026, compared to - $21,017,440 as of December 31, 2025. #### Cash Flow from Operating Activities - Net cash used in operating activities was - $2,979,595 for the three months ended March 31, 2026, compared to - $1,155,514 used for the same period in 2025. #### Cash Flow from Investing Activities - Net cash used in investing activities was - $2,483,609 for the three months ended March 31, 2026, compared to - $215,319 for the same period in 2025. #### Cash Flow from Financing Activities - Net cash provided by financing activities was $14,412,906 for the three months ended March 31, 2026, compared to $2,943,185 for the same period in 2025. #### Customer and Supplier Concentrations - Five key customers accounted for approximately 60% of PMGC Holdings Inc.’s revenue for the three months ended March 31, 2026, with the largest customer contributing 13% ($90,575) from machining casting work. - Two key suppliers represented approximately 43% of the cost incurred in inventory purchases for the three months ended March 31, 2026, with Supplier 1 accounting for 31% and Supplier 2 for 12%. #### Future Outlook and Strategy PMGC Holdings Inc. plans to increase revenue through its multi-strategy investment vehicle, PMGC Capital LLC, by acquiring and managing undervalued assets and pursuing structured financing opportunities. The company also intends to establish new wholly owned subsidiaries for developing and commercializing newly acquired or licensed assets across various industries, and advance clinical development for NorthStrive Biosciences’s clinical assets towards IND applications. Additionally, PMGC Holdings Inc. will pursue further acquisitions of operating business-to-business companies with positive EBITDA and evaluate opportunities like out-licensing biotechnology applications, potential spin-offs, and creating new publicly traded companies such as SPACs. ### Related Stocks - [ELAB.US](https://longbridge.com/en/quote/ELAB.US.md) ## Related News & Research - [NorthStrive® Companies Inc. Co-Advises on Acquisition of A&B Aerospace, Inc.](https://longbridge.com/en/news/286804790.md) - [PMGC Grabs Precision Parts Maker Serving Boeing, Honeywell](https://longbridge.com/en/news/286264149.md) - [Graco Inc. Enters into Definitive Agreement to Acquire Valco Melton, a Global Leader in Precision Adhesive Applications and Quality Assurance Systems](https://longbridge.com/en/news/287221912.md) - [02:00 ETTDConnex opens advanced micro-precision factory in Xiamen, scaling global capabilities for tomorrow's supply chain](https://longbridge.com/en/news/286720707.md) - [The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey | PNGAF Stock News](https://longbridge.com/en/news/286409171.md)